57P Immune competence as a biomarker of response to immune checkpoint inhibition in non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) have become the standard of care for many patients with advanced non-small cell lung cancer (NSCLC). In spite of this, up to half of patients may not derive benefit, and as many as 1 in 4 patients may experience severe immune related adverse events (irAEs). Consequently, there is a critical need to identify biomarkers that can predict response and prognosticate survival. While much work has focussed on tumour biomarkers as predictors of responses here we have examined the immune competence of patients by measuring peripheral immune subsets, cytokine profiling and immune haplotyping.